ArticleBMJ (Clinical research ed.)2012
Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.
Article in BMJ (Clinical research ed.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Effects of Antihypertensive Deprescribing Strategies on Blood Pressure, Adverse Events, and Orthostatic Symptoms in Older Adults: Results From TONE.American journal of hypertension · 2022Trial
- Trial
- Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study.Lipids in health and disease · 2020Trial
- Statin treatment for primary and secondary prevention in elderly patients-a cross-sectional study in Stockholm, Sweden.European journal of clinical pharmacology · 2024Article
- Strategies for Identifying Patients for Deprescribing of Blood Pressure Medications in Routine Practice: An Evidence Review.Current hypertension reports · 2024Review
- Age and Sex Disparities in Cardiovascular Risk Factor Management prior to Stroke: Linked Registry and General Practice Data.Neuroepidemiology · 2024Article
- Inequalities in care delivery and outcomes for myocardial infarction, heart failure, atrial fibrillation, and aortic stenosis in the United Kingdom.The Lancet regional health. Europe · 2023Review
- Antihypertensive Deprescribing in Older Adults: a Practical Guide.Current hypertension reports · 2022Review
- Age-Related Variation in the Provision of Primary Care Services and Medication Prescriptions for Patients with Cardiovascular Disease.International journal of environmental research and public health · 2022Review
- Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial.Frontiers in pharmacology · 2021Article
- Article
- New challenges of geriatric cardiology: from clinical to preclinical research.Journal of geriatric cardiology : JGC · 2017Article
- Article
- Article
- Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.Journal of Alzheimer's disease : JAD · 2016Article
- Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.International journal of endocrinology · 2015Article
- Much more medicine for the oldest old: trends in UK electronic clinical records.Age and ageing · 2015Observational
- Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis.The British journal of general practice : the journal of the Royal College of General Practitioners · 2014Article
- Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis.BMC health services research · 2014Article
- Hypertension and Diabetes Prevalence in Older Persons in Jamaica, 2012.The West Indian medical journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo establish the impact of age and sex on primary preventive treatment for cardiovascular disease in a typical primary care population.
designCross sectional study of anonymised patient records.
participantsAll 41,250 records of patients aged ≥ 40 registered at 19 general practices in the West Midlands, United Kingdom, were extracted and analysed.
main outcome measuresPatients' demographics, risk factors for cardiovascular disease (blood pressure, total cholesterol concentration), and prescriptions for primary preventive drugs were extracted from patients' records. Patients were subdivided into five year age bands up to 85 (patients aged ≥ 85 were analysed as one group) and prescribing trends across the population were assessed by estimating the proportion of patients prescribed with antihypertensive drug or statin drug, or both, in each group.
resultsOf the 41,250 records screened in this study, 36,679 (89%) patients did not have a history of cardiovascular disease and therefore could be considered for primary preventive treatment. The proportion receiving antihypertensive drugs increased with age (from 5% (378/6978) aged 40-44 to 57% (621/1092) aged ≥ 85) as did the proportion taking statins up to the age of 74 (from 3% (201/6978) aged 40-44 to 29% (675/2367) aged 70-74). In those aged 75 and above, the odds of a receiving prescription for a statin (relative to the 40-44 age group) decreased with every five year increment in age (odds ratio 12.9 (95% confidence interval 10.8 to 15.3) at age 75-79 to 5.7 (4.6 to 7.2) at age ≥ 85; P<0.001). There were no consistent differences in prescribing trends by sex.
conclusionsPreviously described undertreatment of women in secondary prevention of cardiovascular disease was not observed for primary prevention. Low use of statins in older people highlights the need for a stronger evidence base and clearer guidelines for people aged over 75.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.